The Latest Cardiac and Vascular News
DENVER, May 10, 2023 /PRNewswire/ — ViewRay, Inc. (Nasdaq: VRAY) (the “Company”) today announced financial results for the first quarter ended March 31, 2023. First Quarter 2023 Highlights Total revenue for the first quarter 2023 was approximately $22.5 million, primarily from three revenue units, compared to approximately $18.9 million, primarily from three revenue units, in the […]
Late-breaking data presented from largest-ever randomized controlled multicenter clinical trial on optimizing patient safety during coronary procedures Philips-hosted symposiums and onsite trainings to empower better heart care through integrated imaging, devices, software, informatics and services Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, is […]
SUNNYVALE, Calif., May 10, 2023 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the first quarter of 2023 and filed its quarterly report on Form 10-Q for the three months ended March 31, […]
– All Four Business Segments Achieved Growth Led by Strong SimpliDerm and CanGaroo Sales – SILVER SPRING, Md., May 10, 2023 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, […]
Announced launch and commercial availability of FUROSCIX® on February 20th Generated net FUROSCIX revenue of $2.1 million Ended Q1 2023 with cash, cash equivalents and short-term investments of $116.1 million Company to host investor conference call and webcast today, Wednesday, May 10, at 4:30pm ET BURLINGTON, Mass., May 10, 2023 (GLOBE […]
SHANGHAI, China and PRINCETON, N.J., May 11, 2023 (GLOBE NEWSWIRE) — LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that CAMZYOS® (mavacamten) has received marketing approval for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) from […]
TN-201 Received Fast Track Designation from the FDA Dosing Complete in Phase 1 Clinical Trial of TN-301; Data Expected in Second Half 2023 Renowned Researchers Drs. Christine Seidman and Alex Marson Join Scientific Advisory Board Announces Formation of Technical Advisory Board with Deep Expertise in Gene Therapy Manufacturing SOUTH SAN […]
Advancement of Additional Cardiac Myosin Inhibitor Expands Specialty Cardiovascular Portfolio SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 randomized, double-blind, placebo-controlled, multi-part, single and multiple ascending dose clinical study of CK-4021586 […]
– NDA submission for etripamil in patients with PSVT currently on track for 3Q23 – Company to host virtual KOL event focused on etripamil for the potential treatment of AFib-RVR on Monday, May 22, 2023 – Topline data from Phase 2 ReVeRA study evaluating etripamil in patients with AFib-RVR expected in 2H, 2023 – […]
McDermott + Bull Partner Ken Dropiewski talks with H.I.G. Capital Managing Director Gwen Watanabe about when they typically invest.
